Abstract:Abstract Background/Aims: Emerging data shows a rise in colorectal cancer (CRC) incidence in young men and women that is often chemoresistant, with potential new risk factors including alterations in the microbiome that remain understudied. We have recently observed altered microbiome with modulation of the gut immune response through crosstalk between sensors, microbes, and the TGF-β signaling pathway. Interestingly, we observed that human CRC cell lines with disruption of TGF-β had increased sensitivity to cisplatin and other DNA cross-linking agents. Yet at the same time, human CRC with loss of Smad4 portends poor prognosis and resistance to chemotherapy. Therefore, it was unclear whether the epithelial loss of Smad4 or stromal loss of Smad4 expression could be responsible for chemoresistance. Here, we investigated the role of chemotherapy with disruption of TGF-β signaling and an altered intestinal microbiome in colorectal carcinogenesis. Methods: CRCs induced by azoxymethane (AOM)/dextran sodium sulfate (DSS) in wild type (WT) and TGF-β signaling deficient mice (SKO: Smad4+/- and Smad4+/-/Sptbn1+/-) were treated with 5-Fluoro-Uracil (5FU). Shotgun metagenomic sequencing was performed in fecal samples from WT and SKO mice before and after treatment. Results: Our analyses revealed that SKO mice are more susceptible to AOM/DSS induced CRC as demonstrated by increased multiplicity (SKO vs WT: 10.25±1.5 vs 5.5±1.4, p=0.01) and tumor size (SKO vs WT: 3.63±0.7mm vs 2.17±0.3mm, p=0.02). CRC that develops in mice with disrupted TGF-β signaling is chemoresistance to 5FU and progress to liver metastasis confirmed by histological and immunohistochemical analysis. Interestingly, SKO mice display a unique gut microbiome signature compared to the WT mice. SKO mice had significantly reduced abundances of beneficial species of B. vulgutus (0.056±0.0078 vs 0.018±0.0052) and P. distasonis (0.007±0.001 vs 0.003±0.001). In addition to E. Boltae, and Mordavella sp., the relative abundance of Bacteroides was significantly reduced in AOM/DSS induced tumors and recovered to basal levels after 5FU treatment in WT mice but not in SKO mice with deficient TGF-β signaling (e.g. Bacteroides dorei: WT basal vs WT-CRC vs WT-CRC-5FU: 0.28±0.08 vs 0.05 ±0.01 vs 0.45±0.17; SKO basal vs SKO CRC vs SKO-CRC-5FU: 0.13±0.02 vs 0.06 ±0.007 vs 0.07±0.01). Conclusions: Our study identified unique gut microbiome species corresponding to 5FU resistance through interactions with key immune-related pathways such as TGF-β members that are implicated in CRC development and drug resistance. The in vivo studies suggest a cell non-autonomous role of the TGF-β pathway in CRC chemoresistance. Collectively, the altered microbiome composition from impaired TGF-β signaling could promote colorectal carcinogenesis and drug resistance. Manipulating these specific species associated with 5FU could potentially increase drug response. Citation Format: Shuyun Rao, Zhuanhuai Wang, Xiaochun Yang, Lindsay M. Hopson, Stephanie S. Singleton, Wilma Jogunoori, Raja Mazumder, Vincent Obias, Paul Lin, Bao-Ngoc Nguyen, Michael Yao, Larry Miller, Jon White, Lopa Mishra. Colorectal carcinogenesis in Smad4/SPTBN1 mutants alter the intestinal microbiome and resistance to 5FU [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 1405.

The diapause-like colorectal cancer cells induced by SMC4 attenuation are characterized by low proliferation and chemotherapy insensitivity

Spindle Pole Body Component 24 Homolog Potentiates Tumor Progression Via Regulation of SRY-box Transcription Factor 2 in Clear Cell Renal Cell Carcinoma.

Colorectal carcinogenesis in Smad4/SPTBN1 mutants alter the intestinal microbiome and resistance to 5FU.

The Interaction Between PDCD4 and YB1 is Critical for Cervical Cancer Stemness and Cisplatin Resistance.

SMC4 knockdown inhibits malignant biological behaviors of endometrial cancer cells by regulation of FoxO1 activity

SET Domain-Containing Protein 4 Epigenetically Controls Breast Cancer Stem Cell Quiescence

SMC4 serves as a potential marker for the diagnosis and prognosis of colon adenocarcinoma

Integrated multi-omics characterization of SMAD4 mutant colorectal cancer

Cancer Stem Cell Regulated Phenotypic Plasticity Protects Metastasized Cancer Cells from Ferroptosis

Endogenous Authentic OCT4A Proteins Directly Regulate FOS/AP-1 Transcription in Somatic Cancer Cells.

The SMARCA4R1157W mutation facilitates chromatin remodeling and confers PRMT1/SMARCA4 inhibitors sensitivity in colorectal cancer

Downregulation of Smc1a Inhibits Growth and Increases Apoptosis and Chemosensitivity of Colorectal Cancer Cells

Smad4 Sequestered in SFPQ Condensates Prevents TGF-β Tumor-Suppressive Signaling.

Exploring the molecular mechanisms and therapeutic potential of SMAD4 in colorectal cancer

The SMARCA4 R1157W mutation facilitates chromatin remodeling and confers PRMT1/SMARCA4 inhibitors sensitivity in colorectal cancer

The SMARCA4<SUP>R1157W</SUP> mutation facilitates chromatin remodeling and confers PRMT1/SMARCA4 inhibitors sensitivity in colorectal cancer

CHD4 Has Oncogenic Functions in Initiating and Maintaining Epigenetic Suppression of Multiple Tumor Suppressor Genes

SMAD4 Limits PARP1 dependent DNA Repair to Render Pancreatic Cancer Cells Sensitive to Radiotherapy

An Embryonic Diapause-like Adaptation with Suppressed Myc Activity Enables Tumor Treatment Persistence

Mir-449A Inhibits Colorectal Cancer Progression by Targeting SATB2

SMAD4 depletion contributes to endocrine resistance by integrating ER and ERBB signaling in HR + HER2− breast cancer